The current study emphasized the functional interaction of SRC, ETS, and IKK/NF-κB to control proliferation and survival, as well as on the efficacy of combining Dasatinib with the IKKβ inhibitor, CmpdA, to inhibit cell proliferation through simultaneous inhibition of NF-κB in cisplatin-resistant HNSCC. This evidence concerns the gene NFKB1 and head and neck squamous cell carcinoma.